Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 3/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.31 |
| ▸ | DRD2 | P14416 | 7/20 | 0.31 |
| ▸ | DRD4 | P21917 | 4/20 | 0.31 |
| ▸ | DRD3 | P35462 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22906473 | 0.98 | DPP4 (0.35) | DPP4NCF1CHRNA7MAPTGBA1 | |
| SCHEMBL18850696 | 0.98 | DPP4 (0.35) | DPP4NCF1CHRNA7MAPTGBA1 | |
| SCHEMBL20180742 | 0.84 | DPP4 (0.34) | DPP4NCF1CHRNA7MAPTGBA1 | |
| SCHEMBL23560142 | 0.83 | DRD2 (0.35) | DPP4NCF1CHRNA7MAPTGBA1 | |
| SCHEMBL15976248 | 0.83 | GBA1 (0.39) | DPP4NCF1CHRNA7MAPTGBA1 | |
| SCHEMBL18685242 | 0.83 | DPP4 (0.40) | DPP4GBA1DRD2DRD4DRD3 | |
| SCHEMBL21106182 | 0.82 | KDM4E (0.37) | DPP4NCF1CHRNA7MAPK14POLB | |
| SCHEMBL22856476 | 0.82 | KDM4E (0.37) | DPP4NCF1CHRNA7MAPK14POLB | |
| SCHEMBL23806873 | 0.82 | KDM4E (0.34) | DPP4NCF1CHRNA7MAPK14DRD2 | |
| SCHEMBL22790885 | 0.82 | NCF1 (0.33) | DPP4NCF1CHRNA7MAPK14DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220008-A1 | MULTIMERIC BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220008-A1 | MULTIMERIC BICYCLIC PEPTIDE LIGANDS | CD40, TNFSF11, TNFRSF9 | DPP4 233/4885NCF1 2004/4885CHRNA7 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.